Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new Delphi consensus statement published in JAMA Dermatology officially names oral JAK inhibitors as the first-line treatment for adults with severe alopecia areata. Three FDA-approved options are now available, and experts stress that treatment should be continuous and long-term. The guidance aims to help clinicians skip older, less effective therapies and get patients to effective care sooner.
A landmark Delphi consensus statement, published in JAMA Dermatology and developed in partnership with the National Alopecia Areata Foundation and the American Hair Research Society, has officially established oral JAK inhibitors as the first-line treatment for adults with severe alopecia areata in the U.S. The guidance fills a critical gap — while effective FDA-approved therapies have existed since 2022, there was no clear framework for how to use them.
The consensus, reached by 31 U.S. dermatologists across three rounds of surveys, emphasizes that treatment should be continuous, long-term, and uninterrupted. If a patient doesn't respond adequately after six months, clinicians should switch to a different JAK inhibitor, adjust the dose, or add adjunctive therapies like minoxidil, corticosteroids, or dupilumab. Older treatments — including antihistamines, anthralin, and platelet-rich plasma injections — did not meet the consensus threshold.
Key Takeaways:
Why it matters: Alopecia areata is more than a cosmetic condition — it can deeply affect patients' mental health and daily functioning. This consensus gives clinicians a clear, standardized roadmap to deliver effective, patient-centered care from the start.
